Last updated on May 2018

Phase 4 Study to Evaluate the Effect of Velaglucerase Alfa (VPRIV ) on Patients With Type 1 Gaucher Disease Through the IV Administration of VPRIV Over 2 Years

Brief description of study

To evaluate the effect of VPRIV therapy on patients with type 1 Gaucher disease by measuring the change in the lumbar spine (LS) and bone mineral density (BMD) after 24 months of treatment.

Clinical Study Identifier: NCT02574286

Contact Investigators or Research Sites near you

Start Over

Divya Vats, MD

Kaiser Permanente
Los Angeles, CA United States
  Connect »

Jaime Vengoechea Barrios, MD

Emory Genetics
Decatur, GA United States
  Connect »

Heather Lau, MD

NYU School of Medicine - Hospital
New York, NY United States
  Connect »

Priya Kishnani, MD

Duke University Medical Center
Durham, NC United States
  Connect »

Can Ficicioglu

The Children's Hospital of Philadelphia
Philadelphia, PA United States
  Connect »

Ari Zimmerman, MD

Gaucher Clinical Department of Medicine
Jerusalem, Israel
  Connect »

Jesus Villarrubia Espinosa, MD, PhD

Hospital Universitario Ramon y Cajal
Madrid, Spain
  Connect »

Pilar Pilar, MD

Hospital Quironsalud Zaragoza
Zaragoza, Spain
  Connect »

Patrick B Deegan, MD

Addenbrooke's Hospital
Cambridge, United Kingdom
  Connect »

Derralynn A Hughes, MA, DPhil, ...

Royal Free Hospital
London, United Kingdom
  Connect »

Joel Charrow, MD

Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, IL United States
  Connect »